We design and apply unique patient-based cellular assays for large-scale phenotypic screening, leaning on the power of AI-driven image analysis. Integrated from bed to bench and back to bed, we aim to generate most efficient first-in-class therapeutic molecules for next generation medicine.
Expertise
From patient-based disease models to novel therapeutic molecules.
Pipeline
Innovation holds the key. Our pipeline of drug discovery programs.
Partner with us
Initiate, codevelop or support our discovery programs.
Newsroom
Keep posted about
our latest developments
and achievements
Meet us in Denver
We will participate at this year’s Keystone Symposium on Modern Phenotypic Drug Discovery: From Chemical Biology to Therapy that will take place from May 22nd – May 25th 2022 in...
Ksilink engaged in EnvironMENTAL
Ksilink proudly takes part of the EC funded EnvironMENTAL consortium. Want to know more? You are invited to join a series of seminars! EnvironMENTAL aims at identifying the...
First success for Personalized Functional Profiling (PFP) of gastro-intestinal cancers
Ksilink proudly announces the publication of exciting results in the journal “Cancer Biology & Therapy”. In fact, the technology for Personalized Functional Profiling (PFP) of...
They trust us
“Patient-derived disease models used for phenotypic drug discovery purposes carry a huge potential. We strongly believe in Ksilink as a key player for effectively bridging the gap between scientific excellence and the pharma industry.”
Jacques Volckmann, Head of R&D, Sanofi, France
“Ksilink’s capacities to apply patient-derived disease models for high-throughput, high-content screening by using AI-driven deep learning computation is outstanding.”
Wolfram Zimmermann, CSO, Myriamed GmbH, Germany
“Bridging the gap between academic clinical research and industry is key to enable the precision medicine of tomorrow. We see big value in the ability of Ksilink to translate clinical expertise into treatment for diseases with high unmet medical need .”
Andreas Meyer-Lindenberg, Director and CEO, Central Institute of Mental Health, Germany
“Phenotypic screening using most authentic disease models is clearly paving the way towards next generation medicine. We strongly believe in Ksilink’s potential, allowing the generation of valuable first-in-class therapeutic molecules.”
Bert Klebl, Managing Director of Lead Discovery Center, Germany